A new fat-based injectable is reshaping non-surgical body contouring. Plastic Surgery Practice examines the science and clinical adoption of alloClae with Tiger Aesthetics President Caroline Van Hove and Dr David Shafer.

As the aesthetic medicine industry shifts toward more regenerative, natural-looking solutions, a new class of treatment is entering the spotlight. alloClae, a first-of-its-kind structural adipose tissue allograft, is redefining the landscape of non-surgical body contouring. Designed to address the growing demand for biologically compatible treatments—especially among patients experiencing volume loss from rapid weight loss or aging—alloClae offers a shelf-stable, ready-to-use option that restores volume using purified human fat tissue.

To understand the science, strategy, and clinical value behind alloClae, Plastic Surgery Practice spoke with Caroline Van Hove, president of Tiger Aesthetics, the company behind this innovation. She shares insight into the technology’s development and the growing patient demand for body treatments that work with, not against, natural biology. We also hear from David Shafer, MD, FACS, a double board-certified plastic surgeon in New York City, who offers a clinician’s perspective on how alloClae fits into modern aesthetic practice.

Caroline Van Hove: Aesthetic medicine is undergoing a profound shift—away from artificial fillers and short-term solutions toward treatments that work in harmony with the body’s natural biology. At the forefront of this evolution is alloClae: the first structural adipose tissue allograft designed specifically for aesthetic body contouring. Tiger Biosciences has a long history of human cell and tissue processing expertise, and its subsidiary, Tiger Aesthetics’ is focused on developing transformative technologies such as alloClae.  

This is not just a product innovation—it’s a new category in aesthetic medicine. By offering a biologically compatible, high-performance option for structural volume restoration, alloClae is redefining what’s possible in non-surgical body contouring. As the industry pivots toward more regenerative approaches, alloClae stands as a glimpse into the future: a future where beauty and biology are no longer at odds but working together.

The clinical need for this innovation is clear. According to a 2025 consumer survey, 84% of aesthetic patients seek treatments that work with their body’s own regenerative processes. Meanwhile, the rapid rise in weight loss medication usage has led to an increased demand for volume restoration, particularly in the hips, buttocks, and breasts. Traditional options—autologous fat transfer and synthetic injectables—come with limitations ranging from invasiveness to lack of longevity. alloClae presents a new path forward.

PSP: From a technology standpoint, what distinguishes alloClae from other non-invasive body contouring solutions currently on the market?

Van Hove: alloClae is not a synthetic filler or biostimulant. It is made from purified human fat tissue, processed to preserve the natural 3D structure of adipocytes and the extracellular matrix (ECM). This proprietary approach maintains collagen, elastin, and naturally occurring growth factors that support tissue integration, cellular regeneration, and lasting volume restoration. The result is a shelf-stable, ready-to-use product that offers immediate, targeted volume with minimal downtime—without surgery.

PSP: What kind of clinical validation or physician feedback helped shape the final product, and how are you continuing to gather real-world data post-launch?

Van Hove: We have had the privilege of working with a select group of physicians since fall of 2024 to solicit their feedback on the product, its clinical application, and how to best train providers on the use of the product and the broader launch of the product in 2026. This group has provided us with a wealth of information and feedback. In parallel, we are conducting a clinical study of alloClae for the use of hip dips in patients. The study is currently running across five sites in the United States and we are following these patients 1, 3, 6, and 12 months post-treatment to assess patient satisfaction and retention of the product.  

PSP: What kind of support or resources does Tiger Aesthetics provide to practices adopting alloClae—both from a clinical training and business integration standpoint?

Van Hove: Tiger provides practices with robust training from our Early Clinical Experience physicians through in-person, virtual, and over-the-shoulder events. We also provide practices with all relevant marketing resources so they can properly launch and successfully integrate alloClae into their practice.

PSP: As the aesthetic industry shifts toward less invasive solutions, how is Tiger Aesthetics positioning itself to lead or respond to this evolution over the next 5 years?

Van Hove: At its core, Tiger Aesthetics is a company founded upon a deep expertise in tissue engineering which has led the development of disruptive innovation and improved patient care in many other areas of healthcare. With much advancement needed in the field of medical aesthetics as patients seek more regenerative solutions that are both restorative in volume and in confidence, Tiger intends to lead the creation and introduction of a new class of cell and human tissue products, specifically designed for minimally-invasive aesthetic use. Starting with the launch of alloClae, the first allogeneic structural adipose tissue product for non-invasive body contouring, we seek to harmonize patients’ desire for natural beauty with biologically compatible & long-lasting aesthetic treatments.  

While Van Hove lays out the vision and scientific foundation behind alloClae, it’s in the hands of experienced physicians that the product’s real-world impact comes into focus. One of the earliest adopters, Shafer has incorporated alloClae into his New York City practice as part of a broader effort to meet evolving patient expectations. As interest grows in subtle, natural enhancement—especially among patients who have undergone dramatic body changes—Shafer sees alloClae as a timely, biologically sound alternative to fat grafting and synthetic fillers. His clinical experience offers a front-line look at how this new category is reshaping aesthetic care.

PSP: What clinical gap does alloClae fill in the current body contouring landscape, and how does it compare to other non-invasive modalities in terms of results and patient selection?

David Shafer, MD, FACS: In the age of Ozempic and dramatic weight loss with deflated breasts and butts, the release of alloClae is happening at the perfect time. While fat grafting is a great procedure, if the patient has lost significant weight and has no fat to transfer, our only options are off the shelf fillers and now alloClae. Fillers are good for small areas like the cheeks, but become cost prohibitive for larger areas. They also do not offer a permanent result such as fat grafting. That is where alloClae comes in. It is literally an off the shelf fat grafting option that allows us to inject much higher volumes for significant results.  

PSP: You’ve described alloClae as a “low-risk” and “natural” option—can you walk us through the treatment mechanism and what makes it different from other minimally invasive technologies?

Shafer: There is nothing better than replacing like with like. In the case of alloClae, we are replacing lost fat volume or enhancing fatty areas with essentially new fat architecture. While other injectables are nice in the right situations, only alloClae is truly the natural injectable to use. As we see with our patients when they return after treatments, the injected areas look and feel just like normal fat. Nothing is without risk, but the alloClae injections are very low risk—especially compared to full surgery and other more invasive procedures.  

PSP: Many patients are increasingly seeking subtle aesthetic enhancements. How has this shift in patient expectations influenced your approach to consultations and treatment planning?

Shafer: Each patient should be evaluated individually and a customized plan developed. When plastic surgeons use a cookie cutter approach, that is when patients don’t get natural results. It’s the artistic side of plastic surgery which can help patients enhance their appearance while still looking natural. alloClae gives us a new tool for natural enhancement of moderate volume deficits with remarkable results.  

PSP: As a surgeon accustomed to both surgical and non-surgical body contouring, how do you evaluate when a patient is best suited for alloClae versus more traditional procedures?

Shafer: An ideal candidate for alloClae would be one with moderate volume deficit with either no fat of their own to transfer or the desire to avoid the harvesting of fat. allocale gives us a fast, safe and effective method for essentially off the shelf fat grafting. alloClae does not replace traditional surgery or non-invasive procedures. What it does is help us take the results to the next level.  

PSP: Looking ahead, do you see technologies like alloClae expanding the role of non-surgical treatments in private practice—and what implications might this have for revenue models and clinical workflows?

Shafer: There is no question that alloClae will quickly become incorporated into most practices. alloClae is a new category of treatment, not just a new generation of an established treatment. The time savings of off-the-shelf treatments cannot be overstated. By enhancing already established treatments and novel new uses, alloClae is here to stay. PSP

Photo: Tiger Aesthetics